AU3804800A - Novel epothilone derivatives, method for producing them and their pharmaceuticaluse - Google Patents
Novel epothilone derivatives, method for producing them and their pharmaceuticaluseInfo
- Publication number
- AU3804800A AU3804800A AU38048/00A AU3804800A AU3804800A AU 3804800 A AU3804800 A AU 3804800A AU 38048/00 A AU38048/00 A AU 38048/00A AU 3804800 A AU3804800 A AU 3804800A AU 3804800 A AU3804800 A AU 3804800A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceuticaluse
- producing
- epothilone derivatives
- novel epothilone
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003883 epothilone derivatives Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19908760 | 1999-02-18 | ||
| DE19908760A DE19908760A1 (en) | 1999-02-18 | 1999-02-18 | New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators |
| PCT/EP2000/001331 WO2000049019A2 (en) | 1999-02-18 | 2000-02-18 | Novel epothilone derivatives, method for producing them and their pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3804800A true AU3804800A (en) | 2000-09-04 |
Family
ID=7899229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU38048/00A Abandoned AU3804800A (en) | 1999-02-18 | 2000-02-18 | Novel epothilone derivatives, method for producing them and their pharmaceuticaluse |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3804800A (en) |
| DE (1) | DE19908760A1 (en) |
| WO (1) | WO2000049019A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| ATE434438T1 (en) * | 2001-02-27 | 2009-07-15 | Novartis Pharma Gmbh | COMBINATION CONTAINING A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTHILONE DERIVATIVE |
| IL157443A0 (en) * | 2001-03-14 | 2004-03-28 | Bristol Myers Squibb Co | Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent |
| AU2008203233B2 (en) * | 2001-07-19 | 2010-04-29 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| WO2003022844A2 (en) * | 2001-09-06 | 2003-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones intermediates thereto and analogues thereof |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
| DK1483251T3 (en) | 2002-03-12 | 2010-04-12 | Bristol Myers Squibb Co | C3-cyano-epothilone derivatives |
| BR0311714A (en) * | 2002-06-10 | 2005-03-01 | Novartis Ag | Combinations comprising epothilones and their pharmaceutical uses |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| PT1506203E (en) | 2002-08-23 | 2007-04-30 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| CN101360494A (en) * | 2005-11-22 | 2009-02-04 | 斯克里普斯研究学院 | Chemical Synthesis of Epothilones with High Efficiency |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
| DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
| EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
| WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
| WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
| EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1186606E (en) * | 1995-11-17 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | DERIVATIVES OF THE EPOTILONE ITS PREPARATION AND UTILIZATION |
| US7407975B2 (en) * | 1997-08-09 | 2008-08-05 | Bayer Schering Pharma Ag | Epothilone derivatives, method for producing same and their pharmaceutical use |
| DE19826988A1 (en) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
-
1999
- 1999-02-18 DE DE19908760A patent/DE19908760A1/en not_active Withdrawn
-
2000
- 2000-02-18 WO PCT/EP2000/001331 patent/WO2000049019A2/en not_active Ceased
- 2000-02-18 AU AU38048/00A patent/AU3804800A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000049019A3 (en) | 2001-03-01 |
| DE19908760A1 (en) | 2000-08-24 |
| WO2000049019A2 (en) | 2000-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3804800A (en) | Novel epothilone derivatives, method for producing them and their pharmaceuticaluse | |
| AU4494499A (en) | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof | |
| AU4570900A (en) | Method for the manufacture of paper, and paper machine line | |
| AU2002338336A1 (en) | Epothilone derivatives and methods for making and using the same | |
| AU2001262221A1 (en) | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use | |
| AU1854901A (en) | Novel method | |
| AU3156600A (en) | Novel epothilon derivatives, method for the production thereof and their pharmaceutical application | |
| AU2001264134A1 (en) | Microconnectors and method for their production | |
| AU6567900A (en) | Method for producing security marks and security marks | |
| AU5705000A (en) | Process for selective lactonization | |
| ZA200110388B (en) | Method of producing nitroguanidine- and nitroenamine derivatives. | |
| AU1105301A (en) | Micro-multiport tubing and method for making same | |
| AU3734301A (en) | Method for producing 2-chloro-benzimidazole derivatives | |
| AU2001293907A1 (en) | Method for preparing camptothecin and its derivatives | |
| AU2002227966A1 (en) | Coniosetin and derivatives thereof, method for producing the same and use thereof | |
| AU2001262229A1 (en) | Cyclipostins, a method for their production and the use of the same | |
| AU5214300A (en) | Method for producing 2,2,4,4-tetra-substituted 1,3,5-cyclohexanetriones | |
| AU3843900A (en) | Microbiological production method for alpha-l-aspartyl-l-phenylalanine | |
| AU3837100A (en) | Vitamin d derivatives and process for producing the same | |
| AU2003264894A1 (en) | Novel method for preparing alpha-glycosylceramides, novel alpha-glycosylceramide derivatives and their uses | |
| AU1283001A (en) | Method for producing alkylhalogenosilanes | |
| AU1141501A (en) | Method for producing hydroxymethylpyridines | |
| AU2002227952A1 (en) | Klainetin and derivatives thereof, method for their production and the use of the same | |
| AU2094700A (en) | Method for producing pyrazolylbenzoyl derivatives and novel pyrazolylbenzoyl derivatives | |
| AU6691600A (en) | Method for producing 4-cyano-2-aminomethylthiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |